Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATE 1: Gemcitabine, Trastuzumab and Erlotinib in Metastatic Pancreatic Adenocarcinoma
NCT01204372Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jun 2010
- Primary completion
- Feb 2012
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, trastuzumab, erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Institut du Cancer de Montpellier. Started Jun 2010; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01204372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204372.